This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …

Importance Lipoprotein (a)(Lp [a]) is associated with atherosclerotic disease and aortic
stenosis. Lp (a) forms by bonding between apolipoprotein (a)(apo [a]) and apo B 100 …

Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Prevention of Cardiovascular Disease in Type 1 Diabetes | New England Journal of Medicine
Skip to main content The New England Journal of Medicine homepage Advanced Search …

Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …

Given the limited accuracy of clinically used risk scores such as the Systematic COronary
Risk Evaluation 2 system and the Second Manifestations of ARTerial disease 2 risk scores …